華潤醫療(01515.HK):2024年歸母淨利潤達5.66億元 同比增加119.6%
格隆匯3月25日丨華潤醫療(01515.HK)發佈公告,截至2024年12月31日止年度,集團報告期共實現綜合營業額人民幣98.55億元(2023年財政年度:人民幣101.08億元),而報告期母公司擁有人應佔年度利潤爲人民幣5.66億元,同比增加119.6%,每股盈利人民幣0.45元。董事會建議派發2024年財政年度的末期股息每股人民幣8.2分。
截至2024年12月31日,集團在中國10個省、市共管理運營105家醫療機構。報告期內,集團自有醫院常規診療門診量和住院量分別約爲1,032萬人次和56萬人次,分別較去年同期增長1.9%及1.0%。
報告期內,醫院業務分部營業額爲人民幣91.85億元,同比下降2.4%。其中,人次指標均實現增長,門診人次增長1.3%,住院人次增長1.0%;受醫保控費影響,門診和住院次均收入分別下降2.4%和4.3%。報告期內,努力通過提質增效降低次均收入下降對醫院業務利潤的影響,醫院業務分部毛利爲人民幣16.53億元,同比下降4.7%,毛利率18.0%;醫院業務分部業績約爲人民幣7.66億元,同比增加20.1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.